Evolution of the raynaud’s syndrome in patients with systemic scleroderma dependent on the applied therapy The study aimed at assessing 45 patients with systemic scleroderma (SS) distributed into 3 groups with various therapy regimens for Raynaud’s syndrome. Treatment outcomes were evaluated after 6 months analyzing duration and frequency of attacks, development of complications and comparative assessment of the quality of life of the studied patients. The patients of the group that administered Pentoxyphilin plus Eprosartan showed superior results.

Studiul a fost axat pe studierea a 45 pacienţi cu sclerodermie sistemică (SS) repartizaţi în 3 grupe cu diferse scheme de tratament a sindromului Raynaud. Rezultatele tratamentului a fost apreciate peste 6 luni analizînd durata, frecvenţa acceselor, dezvoltarea complicaţiilor şi analiza comparativă a calităţii vieţii pacienţilor. Rezultate mai supperioare au demonstrat pacienţii din grupul ce a administrat Pentoxifilina în asociere cu Eprosartanul.